0001179110-19-010682.txt : 20190926
0001179110-19-010682.hdr.sgml : 20190926
20190926182244
ACCESSION NUMBER: 0001179110-19-010682
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190925
FILED AS OF DATE: 20190926
DATE AS OF CHANGE: 20190926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MARINO JAMES J
CENTRAL INDEX KEY: 0001198578
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36020
FILM NUMBER: 191119185
MAIL ADDRESS:
STREET 1: C/O ONCONOVA THERAPEUTICS
STREET 2: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Onconova Therapeutics, Inc.
CENTRAL INDEX KEY: 0001130598
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
BUSINESS PHONE: 267-759-3681
MAIL ADDRESS:
STREET 1: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
FORMER COMPANY:
FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20090526
FORMER COMPANY:
FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS INC
DATE OF NAME CHANGE: 20001226
4
1
edgar.xml
FORM 4 -
X0306
4
2019-09-25
0
0001130598
Onconova Therapeutics, Inc.
ONTX
0001198578
MARINO JAMES J
C/O ONCONOVA THERAPEUTICS
375 PHEASANT RUN
NEWTOWN
PA
18940
1
0
0
0
Common Stock
2019-09-25
4
P
0
7260
1.60
A
16942
D
Warrant (right to purchase)
1.01
2019-09-25
4
H
0
5000
D
2018-02-12
Series A Convertible Preferred Stock
5000
0
D
Warrant (right to purchase)
.1067
2019-09-25
4
P
0
5000
A
2019-09-25
2022-12-31
Series A Convertible Preferred Stock
5000
5000
D
Warrant (right to purchase)
.425
2019-09-25
4
H
0
1472.5
D
2018-05-01
Series B Convertible Preferred Stock
1472.5
0
D
Warrant (right to purchase)
.1067
2019-09-25
4
P
0
1472.5
A
2019-09-25
2022-12-31
Series B Convertible Preferred Stock
1472.5
1472.5
D
These warrants were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01.
The warrants were exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and would expire on the later of (i) the one-year anniversary of the date on which theCompany publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019.
In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).
These warrants were acquired in a public offering, by the Company, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425.
The warrants were exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and would expire on the 18-month anniversary of the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.
In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).
/s/ Mark Guerin as attorney-in-fact
2019-09-26